Abstract
Article AbstractBecause this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text. Sir: Varenicline, an a4ß2 nicotinic acetylcholine partial agonist,has been licensed in the United Kingdom (and approved inthe United States) for the treatment of tobacco dependencesince 2006. Studies have shown varenicline to result in highersmoking cessation rates over placebo, bupropion, and nicotinereplacement therapy (NRT). In the one study conducted todate, varenicline was also seen to be effective in smokers withmental illness, there being no evidence of excess adverse eventsor exacerbation of preexisting conditions.†‹
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
